Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor

Cancer Research

Volumn 58, Issue 19, 1998, Pages 4342-4348

  Orlowski, Robert Z ^a,b,d   Eswara, Jairam R ^b   Lafond Walker, Anne ^b   Grever, Michael R ^a   Orlowski, Marian ^c   Dang, Chi V ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL VIABILITY; CHO CELL; COMBINED IMMUNODEFICIENCY; GROWTH INHIBITION; LYMPHOBLAST; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; APOPTOSIS; BURKITT LYMPHOMA; CELL CYCLE; CELL DIVISION; CELL LINE, TRANSFORMED; CELL SURVIVAL; CELLS, CULTURED; CYSTEINE ENDOPEPTIDASES; FIBROBLASTS; HUMANS; IN SITU NICK-END LABELING; LYMPHOCYTES; MALE; MICE; MICE, SCID; MULTIENZYME COMPLEXES; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, INBRED F344; SERINE PROTEINASE INHIBITORS;

EID: 0032189685     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Orlowski, M. The multicatalytic proteinase complex, a major extralysosomal proteolytic system. Biochemistry, 29: 10289-10297, 1990.
2. Rechsteiner, M., Hoffman, L., and Dubiel, W. The multicatalytic and 26S proteases. J. Biol. Chem., 268: 6065-6068, 1993.
3. King, R. W., Deshaies, R. J., Peters, J-M., and Kirschner, M. W. How proteolysis drives the cell cycle. Science (Washington DC), 274: 1652-1659, 1996.
4. Heinemeyer, W., Kleinschmidt, J. A., Saidowsky, J., Escher, C. and Wolf, D. H. Proteinase yscE, the yeast proteasome/multicatalytic multifunctional proteinase: mutants unravel its function in stress induced proteolysis and uncover its necessity for cell survival. EMBO J., 10: 555-562, 1991.
5. Orlowski, M., and Wilk, S. A multicatalytical protease complex from the pituitary that forms enkephalin and enkephalin-containing peptides. Biochem. Biophys. Res. Commun., 101: 814-822, 1981.
6. Wilk, S., and Orlowski, M. Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex. J. Neurochem., 40: 842-849, 1983.
7. Orlowski, M., Cardozo, C., and Michaud, C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Biochemistry, 32: 1563-1572, 1993.
8. Vinitsky, A., Michaud, C., Powers, J. C., and Orlowski, M. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry, 31: 9421-9428, 1992.
9. Vinitsky, A., Cardozo, C., Sepp-Lorenzino, L., Michaud, C., and Orlowski, M. Inhibition of the proteolytic activity of the multicatalytic proteinase complex (proteasome) by substrate related peptidyl aldehydes. J. Biol. Chem., 269: 29860-29866, 1994.
10. Figueiredo-Pereira, M. E., Berg, K. A., and Wilk, S. A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell. J. Neurochem., 63: 1578-1581, 1994.
11. Imajoh-Ohmi, K. T., Sugiyama, S., Tanaka, K., Omura, S., and Kikuchi, H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem. Biophys. Res. Commun., 217: 1070-1077, 1995.
12. Shinohara, K., Tomioka, M., Nakano, H., Tone, S., Ito, H., and Kawashima, S. Apoptosis induction resulting from proteasome inhibition. Biochem. J., 317: 385-388, 1996.
13. Lopes, U. G., Erhardt, P., Yao, R., and Cooper. G. M. p53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem., 272: 12893-12896, 1997.
14. Sherwood, S. W., Kung, A. L., Ritelman, J., Simoni, R. D., and Schimke, R. T. In vivo inhibition of cyclin B degradation and induction of cell-cycle arrest in mammalian cells by the neutral cysteine protease inhibitor, N-acetylleucylleucylnorleucinal. Proc. Natl. Acad. Sci. USA, 90: 3353-3357, 1993.
15. 2 phases in neuro 2a cells. J. Antibiot. (Tokyo), 48: 344-346, 1995.
16. Fenteany, G., Standaert, R. F., Reichard, G. A., Corey, E. J., and Schreiber, S. L. A β-lactone related to lactacystin induces neunte outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarconia cell line. Proc. Natl. Acad. Sci. USA, 91: 3358-3362, 1994.
17. Drexler, H. C. A. Activation of the cell death program by inhibition of proteasome function. Proc. Natl. Acad. Sci. USA, 94: 855-860, 1997.
18. Wang, X., Gorsope, M., Huang, Y., and Holbrook, N. J. p27Kip1-overexpression causes apoptotic death of mammalian cells. Oncogene, 15: 2991-2997, 1997.
19. Katayose, Y., Kim, M., Rakkar, A. N. S., Li, Z., Cowan, K. H., and Seth, P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res., 57: 5441-5445, 1997.
20. Ryan, K. M., and Birnie, G. D. Myc oncogenes: the enigmatic family. Biochem. J., 314: 713-721, 1996.
21. Eilers, M., Schrim, S., and Bishop, J. M. The MYC protein activates transcription of the α-prothymosin gene. EMBO J., 10: 133-141, 1991.
22. Coppola, J. A., and Cole, M. D. Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment. Nature (Lond.)., 320: 760-763, 1986.
23. Miner, J. H., and Wold, B. J. c-myc inhibition of MyoD and myogenin-initiated myogenic differentiation. Mol. Cell. Biol., 11: 2842-2851, 1991.
24. Land, H., Parada, L., and Weiberg, R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature (Lond.), 304: 596-602, 1983.
25. Penn, L. J. Z., Laufer, E. M., and Land, H. c-Myc: evidence for multiple regulatory functions. Semin. Cancer Biol., 1: 69-80, 1990.
26. Bonham, L., Kwok, J., Chisholm, O., and Symonds, G. Inducible transformation of fibroblasts using a metallothionein-v-myc gene construct. Oncogene, 6: 1073-1077, 1991.
27. Askew, D. S., Ashmun, R. A., Simmons, B. C., and Cleveland, J. L. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene. 6: 1915-1922, 1991.
28. Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69: 119-128, 1992.
29. Shi, Y., Glynn, J. M., Guilbert, L. J., Cotter, T. G., Bissonnette, R. P., and Green, D. R. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science (Washington DC), 257: 212-214, 1992.
30. Saint-Ruf, C., Gerbault-Seureau, M., Viegas-Pequignot, E., Zafrani, B., Cassingena, R., and Dutrillaux, B. Proto-oncogene amplification and homogeneously staining regions in human breast carcinomas. Genes Chromosomes Cancer, 2: 18-26, 1990.
31. Kallioniemi, A., Kallioniemi, O. P., Piper, J., Tanner, M., Stokke, T., Chen, L., Smith, H. S., Pinkel, D., Gray, J. W., and Waldman, F. M. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc. Natl. Acad. Sci. USA, 91: 2156-2160, 1994.
32. Hamilton, S. R. Molecular genetic alterations as potential prognostic indicators in colorectal carcinoma. Cancer (Phila.), 69: 1589-1591, 1992.
33. Hamilton, S. R. Molecular genetics of colorectal carcinoma. Cancer (Phila.), 70: 1216-1221, 1992.
34. Milde-Langosch, K., Decker, G., and Loning, T. Human papillomavirus and c-myc/ c-erbB2 in uterine and vulvar lesions. Virchows Arch. A Pathol. Anat. Hislopathol., 419: 479-485, 1991.
35. Tate, J. E., Mutter, G. L., Prasad, C. J., Berkowitz, R., Goodman, H., and Crum, C. P. Analysis of HPV-positive and -negative vulvar carcinomas for alterations in c-myc, Ha-, Ki-, and N-ras genes. Gynecol. Oncol., 53: 78-83, 1994.
36. Nowell, P. C., and Croce, C. M. Chromosomal approaches to the molecular basis of neoplasia. Symp. Fundam. Cancer Res., 39: 17-29, 1986.
37. Leder, P., Battey, J., Lenoir, G., Moulding, C., Murphy, W., Potter, H., Stewart, W., and Taub, R. Translocations among antibody genes in human cancer. Science (Washington DC), 222: 765-771, 1983.
38. Guerrasio, A., Avanzi, G. C., Pegoraro, L., Estivill, X., Serra, A., Giubellino. M. C., Fierro. M. T., Novarino, A.. Foa, R., and Saglio, G. Rearrangement of the c-mvc oncogene with heavy-chain immunoglobulin enhancer in tumor DNA from an acute lymphoblastic leukemia patient. J. Natl. Cancer lnst., 78: 845-851, 1987.
39. Lombardi, L., Newcomb, E. W., and Dalla-Favera, R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tuinorigenic conversion of EBV-infected human B lymphoblasts. Cell, 49: 161-170, 1987.
40. Klein, G., Giovanella, B., Westman, A., Stehlin, J. S., and Mumford, D. An EBV genome negative cell line established from an American Burkitt lymphoma: receptor characteristics, EBV infectibility, and permanent conversion into EBV positive sublines by in vitro infection. Intervirology, 5: 319-334, 1975.
41. Pfitzner, K. E., and Moffatt, J. G. Sulfoxide-carbodiimide reactions. I. A facile oxidation of alcohols. J. Am. Chem. Soc., 87: 5661-5670, 1965.
42. Gorczyca, W., Gong, J., and Darzynkiewicz, Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res., 53: 1945-1951, 1993.
43. Corbett, T., Valeriote, F., LoRusso, P., Polin, L., Panchapor, C., Pugh, S., White, K., Knight, J., Demchik, L., Jones, J., Jones, L., and Lisow, L. In vivo methods for screening and preclinical testing: use of rodent solid tumors for drug discovery. In: B. A, Teicher (ed.) Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. Totowa, NJ: Humana Press, Inc., 1997.
44. Plowman, J., Dykes, D. J., Hollingshead, M., Simpson-Herren, L., and Alley, M. C. Human tumor xenograft models in NCI drug development. In: B. A. Teicher (ed.), Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. Totowa, NJ: Humana Press, Inc., 1997.
45. Wood, D. C. Fate and metabolism of DMSO. In: S. W. Jacob, E. E. Rosenbaum, and D. C. Wood (eds.). Dimethyl Sulfoxide, Vol. 1. Basic Concepts of DMSO, pp. 133-145. New York: Marcel Dekker, Inc., 1971.
46. Jacob, S. W. Pharmacology of DMSO. In: S. W. Jacob, E. E. Rosenbaum, and D. C. Wood (eds.), Dimethyl Sulfoxide, Vol. 1. Basic Concepts of DMSO, pp. 99-112. New York: Marcel Dekker, Inc., 1971.
47. Mason, M. M. Toxicology of DMSO in animals. In: S. W. Jacob, E. E. Rosenbaum, and D. C. Wood (eds.), Dimethyl Sulfoxide, Vol. 1. Basic Concepts of DMSO, pp. 113-131. New York: Marcel Dekker, Inc., 1971.
48. Van Horssen, P. J., Preijers, F. W., Van Oosterhout, Y. V., and DeWitte, T. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice. Int. J. Cancer, 68: 378-383, 1996.
49. Flavell, D. J., Boehm, D. A., Emery, L., Noss, A., Ramsay, A., and Flavell, S. U. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD-19-and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin alone. Int. J. Cancer, 62: 337-344, 1995.
50. Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., Magrath, I. T., Knowles, D. M., and Dalla-Favera, R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 88: 5413-5417, 1991.
51. 14C]-3,4-dichloroisocoumarin with subunits of pituitary and spleen multicatalytic proteinase complex (proteasomes). Biochemistry, 36: 13946-13953, 1997.